Food Allergy News and Research

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts.

As regulators, the FDA recognizes they have an important task ahead of them that will require them to act expeditiously while undertaking an extremely meticulous and thoughtful review once we receive requests to authorize a COVID-19 vaccine for emergency use or submissions for approval of a COVID-19 vaccine for this population.

Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced the publication of a longitudinal analysis that explored the safety, efficacy and food allergy-related quality of life of long-term treatment with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp, previously known as investigational agent AR101] in patients with peanut allergy.

Even if a child with a food allergy has had it all their life, each growth stage comes with its own concerns and challenges. In the “Spotlight: Transition to Adulthood,” we found that the period when a child moves into adulthood comes with a greater risk when food allergies are involved. It also causes a lot of anxiety for their parents.

Update: If you missed the webinar, we added the video below. We also included some resources on additional information discussed in the webinar, as well as answers to several questions we received. Kids With Food Allergies (KFA) hosted a webinar on May 13, 2021, on the latest research on food allergy anaphylaxis in infants and toddlers. The webinar was presented by: Michael Pistiner, MD, MMSc, pediatric allergist at MassGeneral Hospital for Children in Boston, Massachusetts Melanie Carver,...

The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis—commonly known as allergies—for adults and children six years of age and older.

The Brood X cicadas are here. These are a type of insect that live underground and then emerge from the soil in every 17 years to mate. And there’s a lot of them. If you live anywhere from New York to Tennessee, you’ve probably seen them. Or you’re about to. To most kids (and a lot of adults), this sounds like something out of an action or science fiction movie. As much of the eastern half of the nation experiences this “swarmageddon,” the red-eyed critters are often hard for kids to resist...

Recognizing Severe Allergic Reactions in Infants and Toddlers Anaphylaxis is a severe allergic reaction that can be life-threatening if not treated quickly and properly. But the signs and symptoms can be hard to recognize, especially in infants and toddlers. One of the biggest challenges is that this age group is nonverbal. Infants cannot talk about their symptoms, so parents and doctors may not notice or identify the signs of an allergic reaction. Research also suggests infants and toddlers...

A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun. The observational study of children from birth to age 3 years will examine the origins of allergic disease by integrating interdisciplinary analyses of data from more than 260 biological and environmental samples and survey responses from each of 2,500 families.

Epinephrine is a lifesaving medicine for people with severe allergies. It is important to discuss with your doctor about what is the most appropriate prescription for your family. You may also need to find out which options your insurance provider prefers. This will affect your out-of-pocket costs.

Research to be presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting reveals that peanut sublingual immunotherapy (PNSLIT) is effective and could provide sustained unresponsiveness.

A new case series looking at patients who have positive sunflower seed-specific IgE will be introduced during the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting.